

December 16th, 2020 - 17:00 h.

Meeting Link: www.sapd.es/pmcovid19/
Free inscription with previous registration as from December 14

The official language of the conference is English
Hosted by Dr. Manuel Romero-Gómez (Seville) and Dr. Jesús M. Bañales (San Sebastián), Spain

Organized by:



Supporting Scientific Institutions:



Endorsed by:









SCIENTIFIC INFORMATION

SARS-CoV-2 was discovered in Wuhan (China) in the late 2019 and is responsible of coronavirus disease 19 (COVID-19). COVID-19 has considerable variation in disease behavior, with a large majority of infected persons with mild symptoms or even no symptoms. However, a proportion (10-20%) of them develop severe disease, with a wide range of features, but with common respiratory failure linked to interstitial pneumonia in both lungs and acute respiratory distress syndrome. SARS-CoV-2 became rapidly a pandemic, and currently (30 Oct. 2020) affects to 45 millions of people worldwide and is responsible to 1.18 million deaths.

Over the last months, intense research shed light on SARS-CoV-2 virology and COVID-19 pathobiology, including host inherited and acquired risk factors that participate in the virus infection and/or susceptibility to develop severe disease. These new insights may imply important perspectives for performing new public health policies, as well as to improve the management of patients and the identification of new effective therapies.

OBJECTIVES

The main objective of this meeting is to provide an update on the current knowledge and future directions on the study of SARS-CoV-2 and COVID-19

Specifically, the main objectives of this conference are:

- To know the main features of SARS-CoV-2.
- To understand the systemic changes occurring under COVID-19.
- To know the role of host genetics in the course of biological response to SARS-CoV-2.
- To understand the role of the ABO blood groups in SARS-CoV-2 infection and susceptibility.
- To know acquired risk factors for severe COVID-19.
- To understand the mechanisms leading to severe COVID-19.
- To understand the impact of novel biological evidences for the clinical managements of the disease.

PROGRAMME WEDNESDAY, DECEMBER 16TH

17:00	Welcome and introductory remarks Jesús M. Bañales. IIS Biodonostia. San Sebastián, Spain. Manuel Romero-Gómez. Virgen del Rocío University Hospital. Seville, Spain Ángeles Pérez Aisa. President of the Andalusian Society of Digestive Pathology
17:05	Role of Host Genetics in COVID-19 severity Tom Karlsen. Oslo University Hospital. Oslo, Norway.
17:20	Which is the hominin ancestor carrying risk variant haplotypes? Andre Franke. Institut für Klinische Molekularbiologie. Kiel, Germany.
17:35	Role of the ABO blood group in SARS-CoV-2 infection and disease Luca Valenti. University of Milan. Milan, Italy.
17:50	Sequencing SARS-CoV-2 as an opportunity Federico García. San Cecilio Clinic Hospital. Granada, Spain.
18:05	Personalized and Precision Medicine in COVID-19 Manuel Romero-Gómez. Virgen del Rocío University Hospital. Seville, Spain.
18:20	Panel discussion Chairman: Jesús M. Bañales. IIS Biodonostia. San Sebastian, Spain. Agustín Albillos. Ramón y Cajal University Hospital. Madrid, Spain. Luis Bujanda. IIS Biodonostia. San Sebastián, Spain. María Buti. Vall d'Hebron Hospital. Barcelona, Spain. Javier Fernández. Clinic University Hospital. Barcelona, Spain.
18:50	Innovation Research in the management of the pandemic Isaac Túnez. Secretary General for Research, Development and Innovation. Ministry of Health and Family. Andalusia Regional Government. Spain.

Sponsored by:

19:00

Concluding remarks